EXPRS2.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 18:29):

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark...

Stats
Dzisiejszy wolumen	691 664
Średni wolumen	140 314
Kapitalizacja rynkowa	78.14M
EPS	SEK-0.443 ( 2023-11-16 )
Następna data zysków	( SEK0 ) 2024-05-30
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.580
ATR14	SEK0.0140 (0.92%)

Wolumen Korelacja

Długi: -0.23 (neutral)

Krótki: 0.37 (neutral)

Signal:(56.835) Neutral

ExpreS2ion Biotech Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ExpreS2ion Biotech Korelacja - Waluta/Towar

-0.21
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.47
( neutral )

ExpreS2ion Biotech Finanse

Annual	2023
Przychody:	SEK8.80M
Zysk brutto:	SEK5.15M (58.55 %)
EPS:	SEK-2.08

FY	2023
Przychody:	SEK8.80M
Zysk brutto:	SEK5.15M (58.55 %)
EPS:	SEK-2.08

FY	2022
Przychody:	SEK5.09M
Zysk brutto:	SEK5 000.00 (0.10 %)
EPS:	SEK-3.14

FY	2021
Przychody:	SEK12.23M
Zysk brutto:	SEK4.72M (38.59 %)
EPS:	SEK-1.336

Financial Reports:

No articles found.

ExpreS2ion Biotech

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.